Response to Letter to the Editor: "In Patients Receiving Pembrolizumab, Adverse Effects on the Pituitary Gland, Heart and Kidneys Must Be Excluded".
APA
Inoue S (2025). Response to Letter to the Editor: "In Patients Receiving Pembrolizumab, Adverse Effects on the Pituitary Gland, Heart and Kidneys Must Be Excluded".. Internal medicine (Tokyo, Japan), 64(21), 3177. https://doi.org/10.2169/internalmedicine.5568-25
MLA
Inoue S. "Response to Letter to the Editor: "In Patients Receiving Pembrolizumab, Adverse Effects on the Pituitary Gland, Heart and Kidneys Must Be Excluded".." Internal medicine (Tokyo, Japan), vol. 64, no. 21, 2025, pp. 3177.
PMID
40301045
같은 제1저자의 인용 많은 논문 (4)
- Safe and Effective Use of Nivolumab Monotherapy for Locally Advanced Cutaneous Squamous Cell Carcinoma in a 100-Year-Old Patient.
- Predictive model for pancreatic fistula in minimally invasive surgery for gastric cancer.
- Urinary biomarkers for immunotherapy response in urothelial carcinoma: current status and future outlook.
- Immunoglobulin G4-related Autoimmune Pancreatitis and Hypopituitarism Following Immune Checkpoint Inhibitor Therapy.